• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2 型糖尿病患者无既往心血管疾病史时进行年度心血管筛查试验的影响:四年临床结局。

Impact of Annual Cardiovascular Screening Tests in Patients with Type 2 Diabetes Mellitus without Previous Histories of Cardiovascular Disease: Four-year Clinical Outcomes.

机构信息

Cardiovascular Center, Steel Memorial Yawata Hospital, Japan.

Department of Cardiology, Munakata Suikokai General Hospital, Japan.

出版信息

Intern Med. 2021 Sep 1;60(17):2725-2732. doi: 10.2169/internalmedicine.6893-20. Epub 2021 Mar 15.

DOI:10.2169/internalmedicine.6893-20
PMID:33716290
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8479217/
Abstract

Objective We previously reported that, among asymptomatic patients with type 2 diabetes mellitus (T2DM) without a history of cardiovascular disease (CVD), up to 19% of the patients with myocardial ischemia were detected by annual cardiovascular screening tests (ACVSTs). Thus, the present study assessed the long-term clinical outcomes of ACVSTs in those patients. Methods Six hundred and fifty-seven outpatients with T2DM who received ACVSTs at least once or not at all from April 2014 to March 2018 were defined as the S and NS groups, respectively. The data were compared between these two groups. Results This study revealed that, among outpatients with T2DM in our hospital over those four years, with the increasing frequency of receiving ACVSTs, 1) the frequency of the internal use of statins, anti-platelets, and renin-angiotensin system inhibitors, which are well-known as medications for preventing CVD, significantly increased; 2) low-density lipoprotein-cholesterol and triglyceride levels significantly improved; 3) levels of highly sensitive C-protein, a strong predictors of CVD, were significantly suppressed; 4) the progression of renal dysfunction was significantly suppressed; 5) the cumulative of four-point major adverse cardiovascular events and admissions due to heart failure significantly decreased; and 6) the cumulative of all-cause mortality was significantly suppressed. Conclusions Given the above, it may be important to continue ACVSTs in outpatients with T2DM without a history of CVD for several years.

摘要

目的 我们之前报道过,在没有心血管疾病 (CVD) 病史的 2 型糖尿病 (T2DM) 无症状患者中,通过年度心血管筛查测试 (ACVST) 检测到多达 19%的患者存在心肌缺血。因此,本研究评估了这些患者接受 ACVST 的长期临床结局。

方法 2014 年 4 月至 2018 年 3 月期间,至少接受过一次或未接受过 ACVST 的 657 例 T2DM 门诊患者分别被定义为 S 组和 NS 组,比较两组患者的临床资料。

结果 本研究显示,在过去四年中,我院 T2DM 门诊患者中,随着接受 ACVST 次数的增加:1)内用他汀类药物、抗血小板药物和肾素-血管紧张素系统抑制剂的频率显著增加,这些药物是预防 CVD 的常用药物;2)低密度脂蛋白胆固醇和甘油三酯水平显著改善;3)心血管疾病的强预测因子高敏 C 反应蛋白水平显著降低;4)肾功能不全的进展显著受到抑制;5)四点主要不良心血管事件和因心力衰竭入院的累积发生率显著降低;6)全因死亡率显著降低。

结论 综上,对于无 CVD 病史的 T2DM 门诊患者,连续数年接受 ACVST 可能非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/171b/8479217/e8ee740ef6e0/1349-7235-60-2725-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/171b/8479217/6e704c0a74d3/1349-7235-60-2725-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/171b/8479217/682a8dfbeed9/1349-7235-60-2725-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/171b/8479217/e8ee740ef6e0/1349-7235-60-2725-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/171b/8479217/6e704c0a74d3/1349-7235-60-2725-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/171b/8479217/682a8dfbeed9/1349-7235-60-2725-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/171b/8479217/e8ee740ef6e0/1349-7235-60-2725-g003.jpg

相似文献

1
Impact of Annual Cardiovascular Screening Tests in Patients with Type 2 Diabetes Mellitus without Previous Histories of Cardiovascular Disease: Four-year Clinical Outcomes.2 型糖尿病患者无既往心血管疾病史时进行年度心血管筛查试验的影响:四年临床结局。
Intern Med. 2021 Sep 1;60(17):2725-2732. doi: 10.2169/internalmedicine.6893-20. Epub 2021 Mar 15.
2
Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: a Danish cohort study.新诊断为 2 型糖尿病且正在接受他汀类药物治疗的患者的甘油三酯与心血管事件风险:一项丹麦队列研究。
Cardiovasc Diabetol. 2023 Jul 26;22(1):187. doi: 10.1186/s12933-023-01921-5.
3
Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.心血管事件后 2 型糖尿病患者降糖药物处方的变化:来自 DATAFILE 研究的行动呼吁。
J Am Heart Assoc. 2019 Jul 16;8(14):e012244. doi: 10.1161/JAHA.119.012244. Epub 2019 Jul 4.
4
All-cause mortality and cardiovascular events in a Spanish nonagenarian cohort according to type 2 diabetes mellitus status and established cardiovascular disease.根据 2 型糖尿病状态和已确立的心血管疾病,对西班牙高龄人群的全因死亡率和心血管事件进行分析。
BMC Geriatr. 2022 Mar 18;22(1):224. doi: 10.1186/s12877-022-02893-z.
5
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.美国临床内分泌医师协会和美国内分泌学会血脂异常管理与心血管疾病预防指南
Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL.
6
Silent myocardial ischemia in asymptomatic patients with type 2 diabetes mellitus without previous histories of cardiovascular disease.无心血管疾病既往史的2型糖尿病无症状患者的无症状心肌缺血
Int J Cardiol. 2016 Aug 1;216:151-5. doi: 10.1016/j.ijcard.2016.04.008. Epub 2016 Apr 11.
7
Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study.2 型糖尿病代谢性血脂异常与心血管结局:来自 LOOK AHEAD 研究的结果。
J Am Heart Assoc. 2021 Apr 6;10(7):e016947. doi: 10.1161/JAHA.120.016947. Epub 2021 Mar 17.
8
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.用佩马弗他酯降低甘油三酯以降低心血管风险。
N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5.
9
Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.联合用药依从性和治疗强度指标与他汀类药物和/或依折麦布治疗的动脉粥样硬化或其他心血管危险因素患者心血管结局的相关性。
JAMA Netw Open. 2018 Dec 7;1(8):e185554. doi: 10.1001/jamanetworkopen.2018.5554.
10
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.超越低密度脂蛋白:应对2型糖尿病和代谢综合征中的致动脉粥样硬化脂质三联征。
Am J Cardiovasc Drugs. 2005;5(6):379-87. doi: 10.2165/00129784-200505060-00005.

引用本文的文献

1
Risk factors, outcomes and healthcare utilisation in individuals with multimorbidity including heart failure, chronic kidney disease and type 2 diabetes mellitus: a national electronic health record study.患有心力衰竭、慢性肾脏病和 2 型糖尿病等多种疾病的个体的风险因素、结局和医疗保健利用情况:一项全国性电子健康记录研究。
Open Heart. 2023 Sep;10(2). doi: 10.1136/openhrt-2023-002332.
2
Cohort profile: the Utrecht Cardiovascular Cohort-Second Manifestations of Arterial Disease (UCC-SMART) Study-an ongoing prospective cohort study of patients at high cardiovascular risk in the Netherlands.队列资料简介:乌得勒支心血管队列-动脉疾病的第二次表现(UCC-SMART)研究-一项在荷兰对心血管高危患者进行的正在进行的前瞻性队列研究。
BMJ Open. 2023 Feb 20;13(2):e066952. doi: 10.1136/bmjopen-2022-066952.

本文引用的文献

1
Addendum. 10. Cardiovascular Disease and Risk Management: . Diabetes Care 2020;43(Suppl. 1):S111-S134.附录。10. 心血管疾病与风险管理:《糖尿病护理》2020年;43(增刊1):S111 - S134。
Diabetes Care. 2020 Aug;43(8):1977-1978. doi: 10.2337/dc20-ad08. Epub 2020 Jun 5.
2
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.2 型糖尿病患者用胰高血糖素样肽-1 受体激动剂的心血管结局:系统评价和荟萃分析。
Eur J Prev Cardiol. 2020 Dec;27(18):1922-1930. doi: 10.1177/2047487320903638. Epub 2020 Feb 23.
3
Diabetes and Trajectories of Estimated Glomerular Filtration Rate: A Prospective Cohort Analysis of the Atherosclerosis Risk in Communities Study.
糖尿病与估算肾小球滤过率的轨迹:社区动脉粥样硬化风险研究的前瞻性队列分析。
Diabetes Care. 2018 Aug;41(8):1646-1653. doi: 10.2337/dc18-0277. Epub 2018 Jun 1.
4
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂对糖尿病和蛋白尿患者全因死亡率及肾脏结局的影响:一项系统评价和荟萃分析
Kidney Blood Press Res. 2018;43(3):768-779. doi: 10.1159/000489913. Epub 2018 May 22.
5
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 受体激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者全因死亡率的关联:系统评价和荟萃分析。
JAMA. 2018 Apr 17;319(15):1580-1591. doi: 10.1001/jama.2018.3024.
6
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.SGLT-2 抑制剂与其他降血糖药物相关的心血管事件:CVD-REAL 2 研究。
J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11.
7
Cardiovascular Screening for the Asymptomatic Patient with Diabetes: More Cons Than Pros.无症状糖尿病患者的心血管筛查:弊大于利。
J Diabetes Res. 2017;2017:8927473. doi: 10.1155/2017/8927473. Epub 2017 Dec 14.
8
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病患者的心血管结局:一项荟萃分析。
Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. doi: 10.1016/S2213-8587(17)30412-6. Epub 2017 Dec 6.
9
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes.二甲双胍对心血管疾病的影响:一项对 2 型糖尿病患者随机试验的荟萃分析。
Diabetologia. 2017 Sep;60(9):1620-1629. doi: 10.1007/s00125-017-4337-9. Epub 2017 Aug 2.
10
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.西他列汀对 2 型糖尿病患者肾功能及相应心血管结局的影响:TECOS 研究结果。
Diabetes Care. 2016 Dec;39(12):2304-2310. doi: 10.2337/dc16-1415. Epub 2016 Oct 14.